Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Notes Payables: 2014-2018

Historic Notes Payables for Viking Therapeutics (VKTX) over the last 3 years, with Mar 2018 value amounting to $3.7 million.

  • Viking Therapeutics' Notes Payables was N/A to $3.7 million in Q1 2018 from the same period last year, while for Mar 2018 it was $3.7 million, marking a year-over-year change of. This contributed to the annual value of $3.5 million for FY2017, which is 5.55% up from last year.
  • Latest data reveals that Viking Therapeutics reported Notes Payables of $3.7 million as of Q1 2018, which was up 7.82% from $3.5 million recorded in Q4 2017.
  • In the past 5 years, Viking Therapeutics' Notes Payables registered a high of $3.7 million during Q1 2018, and its lowest value of $304,274 during Q4 2014.
  • In the last 3 years, Viking Therapeutics' Notes Payables had a median value of $3.1 million in 2017 and averaged $3.0 million.
  • Data for Viking Therapeutics' Notes Payables shows a peak YoY skyrocketed of 721.63% (in 2015) over the last 5 years.
  • Quarterly analysis of 5 years shows Viking Therapeutics' Notes Payables stood at $304,274 in 2014, then surged by 721.63% to $2.5 million in 2015, then spiked by 30.78% to $3.3 million in 2016, then climbed by 5.55% to $3.5 million in 2017, then reached $3.7 million in 2018.
  • Its Notes Payables was $3.7 million in Q1 2018, compared to $3.5 million in Q4 2017 and $3.2 million in Q3 2017.